Understanding Chronic Kidney Disease

Diabetic kidney disease (DKD) is the single most common cause of end-stage kidney disease worldwide, responsible for roughly 44 percent of all new dialysis starts in the United States. The progression from early diabetic nephropathy to dialysis typically takes 10 to 20 years, but once established, the decline can accelerate unpredictably.

The pathophysiology of DKD involves multiple interconnected processes. Chronic hyperglycemia damages the glomerular basement membrane and promotes mesangial expansion. Hemodynamic stress from hypertension and hyperfiltration injures the podocytes (specialized cells that form the kidney's filtration barrier). Inflammation driven by NF-kB and other pathways promotes tubular damage and interstitial fibrosis. diabetic kidney disease pathophysiology

Until recently, the treatment options for slowing DKD progression were limited to RAAS blockade (ACE inhibitors or ARBs), strict glucose and blood pressure control, and SGLT2 inhibitors. The FLOW trial has now added semaglutide to this list, creating a triple-pillar approach to kidney protection in diabetic patients.

What the Research Shows

The FLOW Trial: Full Results

The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) was published by Perkovic et al. in the New England Journal of Medicine in 2024. It enrolled 3,533 adults with type 2 diabetes and CKD, defined as eGFR 50 to 75 with UACR 300 to 5,000 or eGFR 25 to 50 with UACR 100 to 5,000. Participants received semaglutide 1 mg weekly or placebo on top of standard care including RAAS blockade.

The primary composite endpoint (sustained 50 percent or greater decline in eGFR from baseline, onset of eGFR below 15, initiation of dialysis or transplant, or death from renal or cardiovascular causes) was reduced by 24 percent (HR 0.76, 95% CI 0.66-0.88, P=0.0003). The trial's independent data monitoring committee recommended stopping enrollment early because the benefit had crossed the pre-specified efficacy boundary.

Individual components: sustained eGFR decline was reduced by 22 percent, ESKD was reduced by 26 percent, kidney death by 44 percent (though numbers were small), and cardiovascular death by 29 percent.

eGFR Preservation

The annual rate of eGFR decline was 1.16 mL/min/1.73m2 per year slower in the semaglutide group. To put this in perspective, the average patient with DKD loses approximately 3 to 5 mL/min/1.73m2 per year. Slowing this by 1.16 means approximately a 25 to 35 percent reduction in the rate of kidney function loss, which could translate to multiple additional years before dialysis is needed.

Albuminuria Response

UACR decreased by approximately 24 percent relative to placebo over 2 years. Albuminuria reduction is both a marker of treatment response and a direct contributor to kidney preservation, as proteins in the filtrate damage tubular cells and promote fibrosis.

Subgroup Analyses

Pre-specified subgroups in FLOW showed consistent benefit regardless of baseline eGFR (above or below 50), baseline UACR (above or below 1,000), HbA1c level, and concomitant SGLT2 inhibitor use. The benefit was maintained in patients already receiving SGLT2 inhibitors (roughly 20 percent of the cohort), suggesting additive kidney protection.

How Ozempic May Help

Ozempic (semaglutide 1 mg) was the exact formulation used in FLOW, making it the most directly evidence-supported option for kidney protection. Its kidney benefits stem from: how Ozempic protects kidneys

Glycemic improvement: Reducing HbA1c by 1.0 to 1.8 percent lowers the glucose burden that drives glomerular basement membrane thickening, mesangial expansion, and AGE-mediated damage throughout the kidney.

Anti-inflammatory effects: Kidney inflammation, measured by tubular injury markers and inflammatory cytokines, was reduced in FLOW participants on semaglutide. CRP decreased by approximately 30 percent, reflecting broad dampening of the inflammatory state that accelerates nephron loss.

Hemodynamic improvement: Blood pressure reduction of 3.4 mmHg systolic provides direct glomerular protection by lowering intraglomerular capillary pressure, the force that pushes proteins through the damaged filtration barrier.

Weight loss and reduced hyperfiltration: Even at the 1 mg diabetes dose, Ozempic produces 4 to 7 kg of weight loss, which can reduce obesity-related hyperfiltration and renal venous compression.

Direct tubular effects: GLP-1 receptors in the proximal tubule promote sodium excretion and may reduce tubular workload, protecting tubular cells from the energy depletion and injury that drive tubulointerstitial fibrosis.

Important Safety Information

Based on FLOW trial results, semaglutide 1 mg has received or is expected to receive a kidney-related FDA indication. This is a major validation of its kidney-protective role.

Key safety considerations in CKD patients include: monitoring for dehydration during GI side effects (nausea 20 percent, diarrhea 13 percent, vomiting 9 percent at the 1 mg dose), checking serum creatinine within 2 to 4 weeks of starting therapy, and coordinating with existing RAAS blocker and SGLT2 inhibitor dosing to avoid compounded dehydration risk.

Ozempic does not require dose adjustment in CKD since it is metabolized by proteolysis. In the FLOW trial, it was safely used in patients with eGFR as low as 25 mL/min/1.73m2. Ozempic dosing in kidney disease

Ozempic carries a boxed warning about thyroid C-cell tumors. It is contraindicated in patients with medullary thyroid carcinoma or MEN2.

Who Might Benefit

Based directly on the FLOW trial population, Ozempic for CKD is appropriate for:

• Adults with type 2 diabetes and CKD stages 2-4 (eGFR 25-75) with albuminuria (UACR 100 or greater)
• Patients already on optimized RAAS blockade who need additional kidney-protective therapy
• Diabetic CKD patients with high cardiovascular risk, given the 29 percent cardiovascular death reduction seen in FLOW
• People whose nephrologist wants to maximize kidney protection using all available evidence-based therapies (RAAS blocker + SGLT2 inhibitor + GLP-1 RA)

For non-diabetic patients with CKD or those whose primary need is substantial weight loss, Wegovy (2.4 mg) may be more appropriate, though it lacks a dedicated kidney outcomes trial.

How to Talk to Your Doctor

The FLOW trial gives you and your doctor a clear evidence base. Consider these approaches:

• Ask your nephrologist directly: "Based on the FLOW trial, should I be on semaglutide for kidney protection?"
• If you are already on an SGLT2 inhibitor and RAAS blocker, ask about adding Ozempic as a third kidney-protective agent
• Discuss practical considerations: injection technique, dose titration schedule, and what to do if you experience nausea or vomiting (particularly around hydration)
• Ask about insurance coverage, as the kidney indication may improve access compared to a diabetes-only rationale

navigating GLP-1 prescriptions for kidney disease

Frequently Asked Questions

How much does Ozempic slow kidney decline?

In the FLOW trial, semaglutide slowed the annual rate of eGFR loss by approximately 1.16 mL/min/1.73m2 per year. Over 5 years, this could preserve roughly 5 to 6 mL/min/1.73m2 of kidney function compared to standard care alone, potentially delaying dialysis by years.

Can I take Ozempic if I am already on an SGLT2 inhibitor?

Yes. Roughly 20 percent of FLOW trial participants were on SGLT2 inhibitors at baseline, and semaglutide provided additional kidney benefit on top of SGLT2 inhibitor therapy. The combination is increasingly used in clinical practice for maximal kidney protection. Monitor hydration carefully with both medications.

At what stage of CKD should I start Ozempic?

The FLOW trial enrolled patients with eGFR 25 to 75, covering CKD stages 2 through 4. Earlier intervention (stage 2-3) may preserve more kidney function over time, but benefit was demonstrated even at eGFR as low as 25. Discuss timing with your nephrologist based on your specific eGFR trend and albuminuria level.

Taking the Next Step

The FLOW trial has cemented Ozempic as a kidney-protective medication for patients with diabetic CKD. Alongside RAAS blockers and SGLT2 inhibitors, it forms part of a powerful triple therapy that addresses multiple pathways of kidney injury simultaneously.

At FormBlends, we help you understand the research that drives your treatment decisions. Talk with your nephrologist about whether Ozempic should be part of your kidney protection plan. GLP-1 medications overview